Today: 29 April 2026
Kyivstar (KYIV) stock slides on Nasdaq as Ukraine telecom bucks market gains
6 January 2026
1 min read

Kyivstar (KYIV) stock slides on Nasdaq as Ukraine telecom bucks market gains

New York, January 6, 2026, 15:45 EST — Regular session

  • Kyivstar shares fall about 4% in afternoon trade, dipping below $13
  • Drop comes even as broader U.S. equities trade higher
  • Investors look to March results release and management call for the next catalyst

Kyivstar Group Ltd (KYIV) shares slid 4.4% on Tuesday, bucking a broader rise in U.S. equities. The stock was down about 60 cents at $12.91 in mid-afternoon trade after touching $12.63, while the S&P 500 proxy SPY was up about 0.6%.

The move matters because Kyivstar remains a thinly traded, Ukraine-linked listing that can swing sharply on positioning and risk appetite. With few pure Ukraine plays in U.S. markets, investors often treat KYIV as a bellwether for sentiment on the country’s economy and operating risks.

Kyivstar listed on Nasdaq in August 2025 after combining with Cohen Circle, a special purpose acquisition company, or SPAC — a shell firm that raises cash and then merges with an operating business. A company prospectus supplement said VEON Amsterdam held 89.6% of Kyivstar’s shares after the listing, and disclosed 7.7 million warrants outstanding; warrants give holders the right to buy shares at a set price and can add supply if exercised.

The selloff also diverged from moves in VEON Ltd, Kyivstar’s ultimate parent, whose U.S.-listed shares were up about 1.6% on the day.

Kyivstar’s most recent corporate updates have focused on keeping its network resilient amid power disruptions and conflict risks in Ukraine. In December, the company said it would acquire a solar power plant operator for about $8.24 million and CEO Oleksandr Komarov said, “Investing in renewable energy is a strategic step.”

The next hard date on traders’ calendars is mid-March. Kyivstar said it will release selected fourth-quarter and full-year 2025 financial and operating results on March 16, 2026, and hold a conference call with senior management on March 17.

But risks remain skewed to headlines: the company operates in a war zone, and renewed infrastructure damage, tougher regulation or weaker consumer spending could hit service quality and cash flow. Investors also watch for any dilution from warrant exercises and for liquidity to thin out quickly in down moves.

Stock Market Today

  • Pershing Square Raises $5 Billion in NYSE IPO Debut
    April 29, 2026, 9:21 AM EDT. Pershing Square (NYSE: PS) and Pershing Square USA (NYSE: PSUS) launched trading on the New York Stock Exchange on April 29, marking a significant $5 billion initial public offering (IPO). The event highlights investor interest in Bill Ackman's hedge fund ventures as the market braces for the Federal Reserve's interest rate decision. Key tech giants Microsoft, Amazon, Alphabet, and Meta, major NYSX ETF components, are set to report earnings after markets close, underscoring a busy trading day. Additionally, Gold Royalty (NYSE American: GROY) marks its five-year anniversary on the exchange, reflecting its sustained market presence. This multifaceted update offers insights into IPO activity and key market events shaping the trading day.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
GE Vernova stock in focus as Vietnam LNG power plant starts operations; Jan. 28 earnings next
Previous Story

GE Vernova stock in focus as Vietnam LNG power plant starts operations; Jan. 28 earnings next

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares
Next Story

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares

Go toTop